It reminds me of an incident in the woods in the dark where I was pronouncing about how you could hear anyone coming from miles away...seconds before three guys on mountain bikes went past.
03.11.2025 23:17 β π 0 π 0 π¬ 1 π 0
ASCO Publications
Paper on sunvozertinib in EGFR exon 20 insertions out in @ASCO JCO. 46% response rate for 200 mg dose. Now FDA approved, but can't seem to get the drug for patients ascopubs.org/doi/full/10....
22.09.2025 21:20 β π 1 π 1 π¬ 0 π 0
Royalty free!
06.09.2025 09:55 β π 0 π 0 π¬ 0 π 0
I think his counterpart at ?Barton Street might have had a nose based nickname?
26.08.2025 21:20 β π 0 π 0 π¬ 0 π 0
Visual abstract for Systemic Therapy for SCLC Rapid Guideline Update:
2.4. Patients with LS-SCLC who have completed concurrent chemoradiotherapy and do not have disease progression should be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy. (Evidence quality: Moderate; Strength of recommendation: Strong)
5.3.1. Patients with LS-SCLC and ECOG PS 3-4 due to SCLC who have been treated with concurrent or sequential chemotherapy and radiotherapy may be offered consolidation immunotherapy (durvalumab) for up to 2 years if there are no contraindications to immunotherapy and there is improvement in PS. (Evidence quality: Low; Strength of recommendation: Conditional)
4.1. In patients with relapsed SCLC with a chemotherapy-free interval of less than 90 days, single-agent systemic therapy may be offered. Preferred agents are topotecan, lurbinectedin or tarlatamab. (Evidence quality: Moderate; Strength of recommendation: Strong)
4.2. In patients with relapsed SCLC with a chemotherapy-free interval of at least 90 days, re-challenge with a platinum-based regimen or single-agent chemotherapy (preferred agents are topotecan, lurbinectedin or tarlatamab) may be offered. (Evidence quality: Moderate; Strength of recommendation: Strong)
Kalemkerian et al J Clin Oncol 2024
asco.org/thoracic-cancer-guidelines
New rapid recommendation update on systemic therapy for small-cell lung cancer from ASCO just published: ascopubs.org/doi/full/10.... #ASCOguidelines #MedSky #OncSky #LCSM
20.11.2024 21:39 β π 16 π 8 π¬ 2 π 0
DEFINE_ME
π¨π₯π Hot off the press! π
We are thrilled to share our latest editorial in journal Annals of #Oncology π"The Best Management for Most Patients with Incurable Cancer is on a Clinical Trial."
#medtwitter #ClinicalTrials
www.annalsofoncology.org/article/S092...
16.11.2024 00:59 β π 4 π 2 π¬ 0 π 0
bought but never used a RPi to make a live train departures screen for the house, utility questionable π
18.08.2024 14:59 β π 0 π 0 π¬ 1 π 0
UK-based lung cancer patient advocate. Used to work in IT. Progressive.
(Donβt try and visit edmonstone.net thereβs nothing there right now)
Honorary Professor UoG and Penn
Neuropathology, TBI, concussion, CTE
FIELD:LONG, CONNECT-TBI, PREVENT:RFC, BrainHOPE, ACME, REPORTER
My name is Gavin.
Write about interesting things in Scottish football.
Including the coefficient, Scottish national team & football finances.
Please come visit me at www.ScottishFootball.info for regular and engaging insights into Scottish football
We are a Social Justice, Medical Education & Cancer Health Disparities Lab within Dana Farber Cancer Institute.
Florez Lab members are agents of change
X: #FlorezLab
IG:@florezlab
Assc. Director CCEP & Thoracic Oncologist @DanaFarberNews & @Harvardmed| Young Lung Cancer | Editor @Jamaonc | Co-founder @LatinasInMed | @Florez_Lab
Emergency Medicine. Edge Witch. House Music. A work in progress, but at least I'm doing the work. Steady is fast.#AHCC π¬πΎπ΄σ §σ ’σ ³σ £σ ΄σ Ώ He/Him
30 years #NHS
#breastcancer Oncologist #Brighton
Chief Medical Officer Macmillan Cancer Support
Professor Clinical Oncology, Manchester UK. Combined rad/med onc aka ClinOnc. Views my own
Consultant Medical Oncologist (OG/HPB/NET) and Clinical Director, Belfast. Husband, Father, fat bloke on a bike and owner of 2 mentally challenged spaniels!!
Consultant and senior lecturer in medical oncology, University of Bristol. Breast cancer, clinical trials and harm v benefit. Rides a bike sometimes
UK Breast and CNS Clinical Oncologist. Singer, food enthusiast, chaotic dancer, indiscriminate fiction devourer. She/her. Views my own.
Clinical Oncologist based in London.
Lung and breast cancer specialist
SABR for ventricular tachycardia
Grateful for all that life has to offer
My views are my own.
Mum, Oncologist, πββ¬ lover, Bit of a leftie, SCD wannabe. Like Eddie the Eagle I try but donβt always succeedβ¦
Walking for well-being, poet, amateur photographer, oncologist, karateka and gardener. Posts mostly on nature, poetry, wellbeing, and garden photos. βRema rhymes with Emmaβ.
Clinical Oncology consultant, co-runs @Book oncology book club, runs cRxeate. Avid reader. Interests: Med ed, med hum, creativity, wellbeing. she/her
Professor of Precision Oncology at Newcastle and Clinical Director NE England Genomic Medicine Service. Interests include drug development especially in thoracic malignancy; biomarkers including cfDNA and treatment of older patients with cancer
Thoracic medical oncologist | Chelsea & Westminster Hospital, London, UK | Chair British Thoracic Oncology Group
Medical Director Professional Practice, CO Faculty, Royal College of Radiologists; Consultant Clinical Oncologist Head & Neck and Lung Cancer, Somerset Foundation Trust. She/her. Views expressed are my own.
STAMPEDE2 Trial Senior Research Fellow at University College London| ST7 Clinical Oncology Registrar at the Royal Marsden Hospital,London | Co-host Trials and Tribulations Podcast with Professor Nick James| Views my own
